Tenaya Therapeutics IncNASDAQ TNYA Stock Report

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of disease-modifying therapies that includes both gene therapies and small molecules discovered internally and developed using its product platforms and core capabilities to target defined sub-populations of patients with rare or prevalent forms of heart disease. Its product platforms include Gene Therapy, Cellular Regeneration and Precision Medicine to discover novel therapies for various forms of heart disease. The Company's lead product candidates include, TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy, TN-301, a small molecule for heart failure with preserved ejection fraction, and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).